Dracen Pharmaceuticals Announces the Initiation of First-in-human...

DRP-104, the Company’s novel broad-acting glutamine antagonist, directly targets tumor metabolism and induces profound anti-tumor immune responses. Extensive Pre-clinical profiling supports single...(PRWeb September 25, 2020)Read the full story at https://www.prweb.com/releases/dracen_pharmaceuticals_announces_the_initiation_of_first_in_human_study_of_drp_104_in_adult_patients_with_advanced_solid_tumors/prweb17423191.htm

Source: PRWeb: Medical Pharmaceuticals - September 25, 2020 Category: Pharmaceuticals Source Type: news